Kempenhaeghe

The Sleep Medicine Centre at Kempenhaeghe is advancing treatment options for epilepsy. Studies aim to lower seizure counts and evaluate long‑term safety of emerging medicines.

• Refractory epilepsy
• Primary generalized tonic‑clonic seizures
• Focal onset seizures
• Dravet syndrome and Lennox‑Gastaut syndrome
• Idiopathic generalized epilepsy
• Adjunctive cannabidiol therapy
• Novel oral agents such as XEN1101 and BHV‑7000

A total of nine trials involving five investigators are currently recruiting or ongoing, offering patients access to cutting‑edge interventions while generating data that could reshape seizure management.

Research at the centre also addresses sleep disturbances that accompany neurological disease. The goal is to improve sleep quality and overall wellbeing through targeted therapies.

• Insomnia management in adults
• Sleep quality in multiple sclerosis
• Impact of cannabidiol on sleep patterns
• Non‑pharmacologic sleep interventions
• Sleep monitoring in patients with epilepsy

By integrating sleep assessments into epilepsy trials, the site provides a holistic view of patient health, supporting better outcomes for both seizure control and restorative rest.